## Highlights of This Issue 753

### SPECIAL FEATURES

#### CCR Translations

755  
Predictive Biomarkers to Anti-VEGF Therapy: Progress toward an Elusive Goal  
Rekha Gyanchandani and Seungwon Kim  
*See article, p. 929*

#### Molecular Pathways

758  
Molecular Pathways: Multimodal Cancer-Killing Mechanisms Employed By Oncolytic Vesiculoviruses  
Douglas J. Mahoney and David F. Stojdil

#### Review

764  
The Definition of Primary and Secondary Glioblastoma  
Hiroko Ohgaki and Paul Kleihues

### HUMAN CANCER BIOLOGY

773  
Lactate Dehydrogenase B Is Required for the Growth of KRAS-Dependent Lung Adenocarcinomas  
Mark L. McCleland, Adam S. Adler, Laura Deming, Ely Cosino, Leslie Lee, Elizabeth M. Blackwood, Margaret Solon, Janet Tao, Li Li, David Shames, Erica Jackson, William F. Forrest, and Ron Firestein

785  
Reciprocal Interactions between Tumor-Associated Macrophages and Osteopontin/CD44 Promote Tumorigenicity in Colorectal Cancer  
Guanhua Rao, Hongyi Wang, Baowei Li, Li Huang, Danfeng Xue, Xiaohui Wang, Haijing Jin, Jun Wang, Yushan Zhu, Youyong Lu, Lei Du, and Quan Chen

798  
SHP2 Is Overexpressed and Inhibits pSTAT1-Mediated APM Component Expression, T-cell Attracting Chemokine Secretion, and CTL Recognition in Head and Neck Cancer Cells  
Michael S. Leibowitz, Raghendra M. Srivastava, Pedro A. Andrade Filho, Ann Marie Egloff, Lin Wang, Raja R. Seethala, Soldano Ferrone, and Robert L. Ferris

---

### CANCER THERAPY: PRECLINICAL

809  
Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer  

821  
Influence of Human OATP1B1, OATP1B3, and OATP1A2 on the Pharmacokinetics of Methotrexate and Paclitaxel in Humanized Transgenic Mice  
Evita van de Steeg, Anita van Esch, Els Wagenaar, Kathryn E. Kenworthy, and Alfred H. Schinkel

833  
Blocked Autophagy Using Lysosomotropic Agents Sensitizes Resistant Prostate Tumor Cells to the Novel Akt Inhibitor AZD5363  
Francois Lamoureux, Christian Thomas, Claire Crafter, Masafumi Kumano, Fan Zhang, Barry R. Davies, Martin E. Gleave, and Amina Zoubaidi

845  
Caspase-Independent Cell Death Is Involved in the Negative Effect of EGF Receptor Inhibitors on Cisplatin in Non–Small Cell Lung Cancer Cells  
Hirohito Yamaguchi, Jennifer L. Hsu, Chun-Te Chen, Ying-Ni Wang, Ming-Chuan Hsu, Shih-Shin Chang, Yi Du, How-Wen Ko, Roy Herbst, and Mien-Chie Hung

855  
Development and Characterization of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Tumorgrafts  
IMAGING, DIAGNOSIS, PROGNOSIS

DNA Methylation as an Adjunct to Histopathology to Detect Prevalent, Inconspicuous Dysplasia and Early-Stage Neoplasia in Barrett’s Esophagus
Muhammad A. Alvi, Xinxue Liu, Maria O’Donovan, Richard Newton, Lorenz Wernisch, Nicholas B. Shannon, Kareem Shariﬀ, Massimiliano di Pietro, Jacques J.G.H.M. Bergman, Krish Ragunath, and Rebecca C. Fitzgerald

The Immune Signature of CD8+ CCR7+ T Cells in the Peripheral Circulation Associates with Disease Recurrence in Patients with HNSCC
Malgorzata Czystowska, William Gooding, Miroslaw J. Szczepanski, Andres Lopez-Abaitero, Robert L. Ferris, Jonas T. Johnson, and Theresa L. Whiteside

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
Priti S. Hegde, Adrian M. Jubb, Dafeng Chen, Nicole F. Li, Y. Gloria Meng, Coen Bernaards, Rebecca Elliott, Stefan J. Scherer, and Daniel S. Chen
See commentary, p.755

Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy
Reda Z. Mahfouz, Ania Jankowska, Quteba Ebrahem, Xiaorong Gu, Valeria Visconte, Ali Tabarriki, Pramod Terse, Joseph Covey, Kenneth Chan, Yonghua Ling, Kory J. Engelke, Mikaël A. Sekeres, Ramon Tiu, Jaroslaw Maciejewski, Tomas Radivojevitch, and Yogen Saunthararajah

CANCER THERAPY: CLINICAL

A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma
David A. Reardon, Morris D. Groves, Patrick T. Wen, Louis Nabors, Tom Mikkelsen, Steve Rosenfeld, Jeffrey Raizer, Jorge Barriuso, Roger E. McLendon, A. Benjamin Suttle, Bo Ma, C. Martin Curtis, Mohammed M. Dar, and Johann de Bono

First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies

LETTERS TO THE EDITOR

Long-term Prospective Population PK Study in GIST Patients—Letter
Etienne Chatelut, Peggy Gandia, Verena Gotta, and Nicolas Widmer

Long-term Prospective Population PK Study in GIST Patients—Response
Ron H.J. Mathijssen, Peter de Bruijn, Karel Eechoute, and Alex Sparreboom

CORRECTION

Correction: Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies

American Association for Cancer Research
ABOUT THE COVER

The image displays a human prostate cell line (PC-3) that has been stained with antibodies against the autophagy marker Light Chain 3 (LC3; green) after rapamycin treatment. During autophagy, LC3-I is converted to LC3-II through lipidation by a ubiquitin-like system involving Atg7 and Atg3 that allows for LC3 to become associated with autophagic vesicles, as shown by green puncta. Tumor cell nuclei are visualized by DAPI (blue). For details, see the article by Lamoureux and colleagues on page 833 of this issue.